The study highlights the mechanism of action of petosemtamab, which is designed to combat cancer by blocking EGFR ligands, promoting internalization and degradation of EGFR in LGR5+ cells, and ...

Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poste ...

How Well Did the Mysterious Antikythera Mechanism Actually Work? Historians think the 2,000-year-old device was used to predict the positions of celestial bodies. A new digital simulation suggests ...

A recent review in Medicine Plus offers profound insights into anthracycline-induced cardiotoxicity (AIC), exploring its mechanisms and therapeutic strategies, contributing to safer oncological ...

Previously known as JNJ-2113, icotrokinra (Protagonist Therapeutics, Johnson & Johnson) has a very specific mechanism of action for the treatment of moderate to severe plaque psoriasis, according ...

Sacubitril/valsartan significantly reduced cardiomyopathy risk by 77% in patients on anthracycline chemotherapy compared to placebo. The SARAH trial highlights the need to identify high-risk ...

SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, a new analysis of a ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes ...

CHICAGO, IL—Taking sacubitril/valsartan (Entresto; Novartis) can help protect against the cardiotoxicity posed by anthracycline chemotherapy for high-risk patients with cancer, results from the ...

The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and ...